|
|||||
|
|
| 治疗阵发性睡眠性血红蛋白尿症药物Eculizumab | |
| 引用本文： | 田娜,叶敏. 治疗阵发性睡眠性血红蛋白尿症药物Eculizumab[J]. 中国新药杂志, 2008, 17(22): 1984-1985 |
| 作者姓名： | 田娜 叶敏 |
| 作者单位： | 中国医学科学院,中国协和医科大学,北京协和医院药剂科,北京,100730 |
| 摘 要： | eculizumab(Soliris)是一种单克隆抗体,是惟一被用于治疗阵发性睡眠性血红蛋白尿症(PNH)的药物,它能抑制末端补体蛋白C5从而减少溶血、血红蛋白尿和输血,改善PNH患者的生活质量.现就其药理学、药动学、临床研究、不良反应等做一综述. |
| 关 键 词： | 阵发性睡眠性血红蛋白尿症 单克隆抗体 |
Eculizumab,an orphan drug for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
|
| TIAN Na,YE Min. Eculizumab,an orphan drug for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)[J]. Chinese Journal of New Drugs, 2008, 17(22): 1984-1985 | |
| Authors: | TIAN Na YE Min |
| Affiliation: | TIAN Na,YE Min(Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences-Peking Union Medical College,Beijing 100730,China) |
| Abstract: | Eculizumab(Soliris) is an orphan drug for the treatment of patients with paroxysmal nocturnal hemoglobinuria(PNH).Eculizumab is a monoclonal antibody against terminal complement protein C5;it can reduce intravascular hemolysis,hemoglobinuria and the need for transfusion,and is associated with improvement in the quality of life in patients with PNH.In this review,we presented the pharmacology,clinical studies,dosage and administration,warnings and precautions,and the use in specific populations. |
| Keywords: | eculizumab |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |